Generation of a Pool of Human Platelet Lysate and Efficient Use in Cell Culture
* Final gross prices may vary according to local VAT.Get Access
Human platelets represent a promising source of bioactive substances as growth factors not just for in vivo wound healing and tissue repair, but also for the expansion of human stem and progenitor cells in vitro. The replacement of fetal bovine serum (FBS) as a standard culture supplement by human platelet-derived growth factors now allows for the GMP-compliant implementation of various cell therapeutics in the growing field of regenerative medicine.
For this purpose a protocol for the preparation of human platelet lysate (HPL) by several freeze–thaw cycles has been developed, resulting in platelet fragmentation and the release of stored growth factors. By pooling up to 15 U of HPL derived from individual blood donors, a virtually standardized product is achieved. The depletion of platelet particles and fragments in a final centrifugation step reduces the risk of alloimmunization against platelet antigens and the formation of aggregates in cell culture.
The successful application of pooled human platelet lysate (pHPL) as a culture medium supplement for the ex vivo propagation of human mesenchymal stem/progenitor cells (MSPCs) and endothelial colony forming progenitor cells (ECFCs) indicates the feasibility of this animal serum-free source of growth factors. Further studies will evaluate efficacy and safety of pHPL.
- Generation of a Pool of Human Platelet Lysate and Efficient Use in Cell Culture
- Book Title
- Basic Cell Culture Protocols
- pp 349-362
- Print ISBN
- Online ISBN
- Series Title
- Methods in Molecular Biology
- Series Volume
- Series Subtitle
- Methods and Protocols
- Series ISSN
- Humana Press
- Copyright Holder
- Springer Science+Business Media, LLC
- Additional Links
- Platelet-rich plasma
- Pooled human platelet lysate
- Buffy coat
- Platelet concentrate
- Platelet-derived growth factors
- Mesenchymal stem/progenitor cells (MSPCs)
- Endothelial colony-forming progenitor cells (ECFCs)
- Industry Sectors
- Editor Affiliations
- ID1. , Experimental Therapeutics, BC Cancer Agency
- ID2. STEMCELL Technologies, Inc.
- Author Affiliations
- 00221. Stem Cell Research Unit Graz and Clinic for Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria
- 00222. Stem Cell Research Unit and Department of Hematology, Medical University of Graz, Graz, Austria
To view the rest of this content please follow the download PDF link above.